The vision for Mesoblast – to become the world leader in novel therapeutic approaches for patients with bone and joint diseases, including adult stem cell therapy for bone fractures and spinal disease, and for regeneration of damaged joint cartilage and intervertebral discs.

unique adult stem cell technology for orthopaedic applications for patients with bone and cartilage degeneration. Repair and regrowth of adult stem cells, Melbourne Australia
 

Mesoblast - adult stem cell technology, regeneration of adult stem cells, repair and regrowth of bone and cartilage Melbourne, Australia

Mesoblast - The adult stem cell company

Mesoblast Limited (ACN 109 431 870) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage.

Mesoblast - The adult stem cell company. The vision for Mesoblast – to become the world leader in adult stem cell therapy for patients with bone and cartilage degeneration

Mesoblast Limited, which listed on the Australian Stock Exchange in December 2004, has the world wide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The technology has achieved outstanding results in pre-clinical in vivo studies in the regeneration and repair of large bone fractures.

The company has also acquired a substantial equity holding in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology.

Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of pre-clinical and clinical milestones.

 

Last Share Price

June 05 - United States FDA Clears Phase 2 Trial for Congestive Heart Failure. Major new market opportunity

April 17 - Mesoblast's cells show long-lasting and sustained effect in knee osteoarthritis

April 09 - Spinal Fusion Clinical Program Update - Accelerated Timetable to Registration Trial

April 07 - U.S. Heart Attack Trial Update - "Most Exciting Stem Cell Therapy in Heart Research Today"

May 2008 - Issue Nine

September 2007 - Issue Eight

March 2007 - Issue Seven

August 2006 - Issue Six